🔎 Trials Near Me

Akèy › Myelofibroz › Maryland

Etid klinik pou Myelofibroz nan Maryland

9 etid pou Myelofibroz ap chèche patisipan nan sit nan Maryland.

Vil nan Maryland

Tèks ofisyèl etid la (Anglè)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • University of Maryland, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04176198

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  • American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07357727

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  • Johns Hopkins University, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • John Hopkins Hospital, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06034002

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  • Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 12, 2026 · NCT05980806

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Baltimore
  • Massive Bio SYNERGY-AI site, Bethesda
  • Massive Bio SYNERGY-AI site, Silver Spring
  • ak 1 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
  • The Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT06479135

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.